Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00982345 · ClinicalTrials.gov registry record · Phase 4
Brain Imaging of Quetiapine Response in Anxious Depression
A Phase 4 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT00982345 is a Phase 4 study that has completed, run by Indiana University. The registered enrollment target is 20 participants.
The verdict
NCT00982345, a Phase 4 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to find out what parts of the brain have increased or decreased connectivity when people are depressed and how Seroquel extended release (XR) changes this connectivity in depressed patients. The genetic samples collected are to look at variation in a gene (serotonin transporter gene), which affects the functioning of the chemical serotonin in the brain.
Interventions
- DRUG quetiapine (Seroquel XR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-03 |
| Est. Completion | 2012-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00982345
The ClinicalTrials.gov registry entry for NCT00982345 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which quetiapine (Seroquel XR) is the first listed.
NCT00982345 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00982345 about?
NCT00982345 is a clinical study titled "Brain Imaging of Quetiapine Response in Anxious Depression". The purpose of this study is to find out what parts of the brain have increased or decreased connectivity when people are depressed and how Seroquel extended release (XR) changes this connectivity in depressed patients. The genetic samples collected are to look at variation in a gene (serotonin tran...
What is the current status of trial NCT00982345?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2009-03. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00982345?
The interventions under investigation include: quetiapine (Seroquel XR) (DRUG).
Who is sponsoring clinical trial NCT00982345?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.